Fujian Cancer Hospital | China
Dr. Zhijian Huang is a distinguished Deputy Chief Physician at the Department of Breast Surgical Oncology at Fujian Medical University Cancer Hospital in Fuzhou, China. With extensive expertise in breast cancer treatment and reconstructive surgery, Dr. Huang has contributed significantly to understanding tumor metastasis mechanisms and immunological factors in breast cancer. He is currently expanding his research at Harvard University Beth Israel Deaconess Medical Center, focusing on molecular pathways and predictive models.
Professional profile👤
Google Scholar
Strengths for the Awards✨
- Extensive Research Contributions: Dr. Huang has an impressive publication record, with 14 peer-reviewed articles, many in high-impact journals such as Frontiers in Oncology, BMC Cancer, and Biosafety and Health. His research spans crucial areas of breast cancer, including tumor metastasis mechanisms, immune microenvironments, and biomarker discovery.
- Interdisciplinary Expertise: His skills in bioinformatics, molecular biology techniques (e.g., CRISPR/Cas9 gene editing), and clinical integration set him apart as a versatile researcher capable of bridging computational and experimental oncology.
- Clinical Impact: Dr. Huang has contributed directly to patient care through advancements in comprehensive breast cancer treatment, breast reconstruction techniques, and real-world studies of therapeutic efficacy.
- Recognition and Leadership: The two prestigious awards he received in 2023 for his work on artificial intelligence in breast cancer diagnostics and immune microenvironments reflect the impact and recognition of his research in the medical community.
- International Collaboration: His postdoctoral research at Harvard University’s Beth Israel Deaconess Medical Center adds a global dimension to his work and highlights his active engagement in cutting-edge breast cancer research.
Education 🎓
Dr. Huang earned his Doctor of Medicine (M.D.) in Clinical Medicine from Southern Medical University in Guangzhou, China, in 2022. Prior to that, he completed his Master of Medicine at Fujian Medical University in 2009 and his Bachelor of Medicine at the same institution in 2005.
Experience 💼
Dr. Huang has been serving at Fujian Medical University Cancer Hospital since 2009, performing breast tumor surgeries, comprehensive treatments, and breast reconstructions. From 2016 to 2017, he trained at the Affiliated Cancer Hospital of Xiangya Medical College, focusing on advanced tumor plastic surgery techniques. In 2024, he joined Harvard University Beth Israel Deaconess Medical Center as a Postdoctoral Researcher, delving deeper into breast cancer mechanisms and therapeutic advancements.
Research Interests On Oncology🔬
His research revolves around tumor metastasis mechanisms, breast cancer immunology, and molecular biology techniques. He is skilled in Western blotting, lentiviral packaging, CRISPR/Cas9 gene editing, and developing mouse models. Dr. Huang also specializes in bioinformatics analysis, employing tools like SPSS and GraphPad Prism.
Awards 🏆
- 2023: Third Prize, Fujian Medical Science and Technology Award for research on ultrasound-assisted artificial intelligence diagnosis of breast cancer, immune microenvironment, and metastatic molecular mechanisms.
- 2023: Third Prize, Fujian Anti-Cancer Association Science and Technology Award for research on immune microenvironment, metastatic molecular mechanisms of breast cancer, and infusion port clinical applications.
Publications 📚
-
Title: Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer
Authors: C Xiao, L Yang, L Jin, W Lin, F Zhang, S Huang, Z Huang
Year: 2022
Citations: 42
-
Title: Application of oncolytic virus in tumor therapy
Authors: Z Huang, H Guo, L Lin, S Li, Y Yang, Y Han, W Huang, J Yang
Year: 2023
Citations: 29
-
Title: A novel XGBoost method to infer the primary lesion of 20 solid tumor types from gene expression data
Authors: S Chen, W Zhou, J Tu, J Li, B Wang, X Mo, G Tian, K Lv, Z Huang
Year: 2021
Citations: 14
-
Title: miRNA-1260b promotes breast cancer cell migration and invasion by downregulating CCDC134
Authors: Z Huang, S Zhen, L Jin, J Chen, Y Han, W Lei, F Zhang
Year: 2023
Citations: 12
-
Title: A novel framework to predict breast cancer prognosis using immune-associated LncRNAs
Authors: Z Huang, C Xiao, F Zhang, Z Zhou, L Yu, C Ye, W Huang, N Li
Year: 2021
Citations: 12
-
Title: HAUS5 is a potential prognostic biomarker with functional significance in breast cancer
Authors: Z Huang, J Yang, W Qiu, J Huang, Z Chen, Y Han, C Ye
Year: 2022
Citations: 10
-
Title: 肝癌病人术后早期肠内与肠外营养支持治疗的比较
Authors: 周东, 刘胜, 应敏刚, 黄峰, 吴贤毅, 黄志坚
Year: 2012
Citations: 10
-
Title: Comprehensive analysis of immune ferroptosis gene in renal clear cell carcinoma: Prognosis and influence of tumor microenvironment
Authors: LH Yang, LZ Xu, ZJ Huang, HH Pan, M Wu, QY Wu, T Lu, YP Zhang
Year: 2022
Citations: 5
-
Title: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer
Authors: W Huang, C Wang, Y Shen, Q Chen, Z Huang, J Liu, X Lin, L Wang, F Wu
Year: 2024
Citations: 4
-
Title: Systematic pan-cancer analysis identifies cGAS as an immunological and prognostic biomarker
Authors: P Chen, X Yang, P Wang, H He, Y Chen, L Yu, H Fang, F Wang, Z Huang
Year: 2023
Citations: 4
Conclusion 🔖
Dr. Zhijian Huang’s illustrious career is marked by a deep commitment to advancing breast cancer treatment through surgical expertise and cutting-edge research. His work continues to shape the future of cancer therapy, bridging molecular insights with clinical applications to improve patient outcomes worldwide.
